GlassScriptPhysician profile
Richard Burton
NPI 1598994287
$13,680.04
in general payments reported to CMS, 2019-2025
34 companies · $2,504 in 2025
The $2,504 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,240 · 2020: $1,464 · 2021: $1,875 · 2022: $1,943 · 2023: $1,962 · 2024: $2,691 · 2025: $2,504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,093 · Education: $65.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,093.04 |
| Education | $65.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,874.07 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $1,447.81 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Corium, LLC | $999.88 | 2021-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $954.42 | 2020-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $941.26 | 2019-2022 | |
| Axsome Therapeutics, INC. | $803.32 | 2022-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $771.71 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $723.12 | 2019-2024 | Dyanavel Xr |
| Lundbeck LLC | $697.01 | 2019-2025 | Rexulti |
| Allergan, INC. | $619.78 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $596.55 | 2019-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $299.35 | 2019-2023 | Trintellix |
| Merck Sharp & Dohme LLC | $297.21 | 2021-2023 | Belsomra |
| Supernus Pharmaceuticals, INC. | $288.68 | 2024-2025 | Qelbree |
| Almatica Pharma LLC | $274.53 | 2022-2024 | Loreev Xr |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $244.90 | 2019-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $230.78 | 2019-2025 | Austedo Xr, Austedo Xr |
| Jazz Pharmaceuticals INC. | $218.28 | 2019-2021 | |
| Bausch Health US, LLC | $212.28 | 2019-2025 | Aplenzin |
| Alkermes, INC. | $200.77 | 2023-2025 | Lybalvi, Aristada |
| Vertical Pharmaceuticals, LLC | $190.88 | 2019-2025 | Relexxii |
| Collegium Pharmaceutical, INC. | $116.66 | 2025 | Jornay Pm |
| Eisai INC. | $115.09 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $94.63 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $79.73 | 2022-2025 | Quviviq, Quviviq |
| Neos Therapeutics, LP | $76.55 | 2019-2024 | Adzenys Xr-Odt |
| Adlon Therapeutics L.P. | $65.26 | 2019-2021 | |
| Alfasigma USA, INC. | $55.17 | 2021-2022 | |
| Shire North American Group INC | $52.73 | 2019 | |
| Biogen, INC. | $51.87 | 2023-2024 | Zurzuvae |
| Noven Therapeutics, LLC | $36.01 | 2024 | Xelstrym |
| Indivior INC. | $20.72 | 2020 | |
| Sage Therapeutics, LLC | $15.41 | 2019 | |
| Owp Pharmaceuticals, INC. | $13.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Burton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.